Familial deletion of the short arm of the D1-chromosome (46, XX, 13 p-) not associated with loss of haptoglobin or catalase activity

This is an instructive description of a child who has a deletion of the short arm of the D 1 (number 13) chromosome. She is mentally retarded and has multiple congenital malformations, catalase and haptoglobin activity, ruling out the possibility that the loci for these systems are present on the deleted segment. The use of autoradiography is discussed. It is stressed that examination of the palmar and plantar dermatoglyphics should be part of the diagnostic work-up for retardation.

Phenylketonuria. Experience at one center in the first year of screening in California

One year's experience with phenylketonuria during the calendar year 1966, the first year for compulsory newborn screening in California, was reviewed. The over-all prevalence rate from reported cases in California during this period was one case per 19,500 persons tested. Fifty-seven persons suspected of having pku were evaluated, and 25 of them were determined to be phenylketonuric. Eleven of the 25 were infants in whom the abnormality was detected through the newborn screening program or because it was detected in a sibling through a screening program. All the newborn phenylketonuric patients were developing normally at the time of last report (although the follow-up periods were short). In nine of the other children, pku was detected because they were retarded. Five retarded children who were diagnosed as phenylketonuric at another clinic were given dietary assistance. Five additional infants had elevated serum phenylalanines but did not have the classic biochemical findings of pku and are being evaluated further. Nine infants with positive screening tests exhibited biochemical and clinical findings consistent with transient tyrosinemia. Eighteen other children were evaluated and found to have no metabolic abnormality. The newborn screening program for pku is of decided benefit in early identification of a group of infants who have a high rate of potentially serious metabolic disease. Early identification permits treatment soon enough to prevent mental retardation. Newly identified patients should be evaluated in a medical setting capable of careful pediatric, biochemical and nutritional surveillance.